Title: Enhanced natural killer cell activity is found in exposed uninfected recipients of hepatitis C-contaminated blood

Short title: NK cells in EU blood recipients

Authors:
Maggie M. Ow 1,2, Doha Hegazy 2, Usama M. Warshow 2, Matthew E. Cramp 2,3
1 Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Grafton, Auckland 1023, New Zealand
2 Hepatology Research Group, Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth PL6 8BT, UK
3 South West Liver Unit, Derriford Hospital, Plymouth Hospitals NHS Trust, Plymouth PL6 8DH, UK

Correspondence:
Dr Maggie M. Ow, Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Grafton, Auckland 1023, New Zealand.
ph +6493074949 ext 25588 / email m.ow@auckland.ac.nz

Word count:
Abstract 234
Text 3803
Abstract

Background
A minority of injecting drug users, termed exposed uninfected (EU), are resistant to hepatitis C (HCV) infection despite repeated low-dose exposures. We identify for the first time a cohort of blood recipients who remained uninfected despite large-dose exposure to HCV-contaminated blood and characterise immune factors that may confer protection.

Methods
Of 1340 blood recipients from the Look Back database who were transfused HCV-contaminated blood, we identified 8 who remained uninfected. In these 8 EUs, we characterised their natural killer (NK) cell populations and HCV-specific T cell responses. Findings were compared with 10 spontaneous resolvers of HCV infection, 10 patients with chronic HCV infection, and 10 healthy controls.

Results
EUs had significantly greater numbers of NK cells with the activating receptor NKp30+ on CD56bright and CD56dim subsets compared with other groups \((p<0.05)\). Following interleukin-2 activation, NK cells of EUs had enhanced cytotoxicity that positively correlated with NKp30 expression \((p=0.02)\). Differences in NKp80 and KIR2DL3 expression were also observed. HCV-specific T cell responses were observed in some EUs but of low amplitude.

Conclusion
Exposure without infection following transfusion of HCV-contaminated blood is a very rare phenomenon and suggests a high level of resistance to infection. Enhanced NK cell activation and killing, with weak HCV-specific T cell responses, were observed many years after
exposure in uninfected recipients and may contribute to protection from HCV acquisition, although additional protective factors are being sought in this important cohort.

**Keywords**

Hepatitis C; exposed uninfected; natural killer cells; innate immunity; natural cytotoxicity receptor; NKp30
Hepatitis C virus (HCV) is an important cause of liver disease with a propensity to establish chronic infection. Only a minority of individuals are able to spontaneously clear the virus, which relies on the host mounting a successful immune response [1-3]. Not all individuals exposed to HCV, however, develop infection. We and others have previously reported on a novel phenotype of injecting drug users (IDUs) who have no evidence of infection, such as viraemia or anti-HCV antibodies (Ab), despite repeated HCV exposure through high-risk practices [4-16]. We have termed these individuals exposed uninfected (EU) [17].

Thus far, studies on EUs have focused on IDUs exposed to low doses of the virus. The phenomenon of exposure without infection has not been previously described in individuals parenterally exposed to large doses of HCV, such as following transfusion of contaminated blood products. In this study, we have identified and characterised a novel cohort of recipients of HCV-contaminated blood products who have no clinical or serological evidence of infection and who appear to be immunologically distinct from spontaneous resolvers (SRs). Innate and adaptive immune factors that might contribute to this protection against HCV were examined, with a focus on natural killer (NK) cells.

NK cells are defined as CD3- CD56+ and play a key part in the early innate response to viral infections. Unlike T and B cells, they do not require priming and so are able to rapidly kill virus-infected cells [18]. Their activation status is governed by surface receptors with activating and inhibitory functions [19]. EU IDUs appear to be immunologically distinct from those with resolved or chronic infection, displaying an enhanced innate immune response [17,20] attributed to increased NK cell activity. Two studies followed a population of IDUs at high risk for HCV exposure and observed that in IDUs who remained uninfected, their NK cells demonstrated increased cytotoxic activity and interferon-gamma (IFN-γ) production.
when compared with IDUs who became infected [7,8]. EU IDUs also possessed NK cells with a specific receptor profile, which might represent a subset with a favourable phenotype that are more readily activated to kill, thereby preventing establishment of infection [7-9]. These findings have thus far been demonstrated in EUs exposed to only low doses of HCV. This study reports on the immune characteristics of a novel cohort of EUs exposed to a much larger inoculum of virus via blood transfusion.
Materials and methods

Study population

The study population consisted of blood recipients identified from the NHS Look Back programme as being exposed to HCV via blood transfusion pre-1991, which was prior to universal HCV donor screening in the UK.

The Look Back programme was established in 1995 to trace and test recipients of blood products previously donated by blood donors who were subsequently found to be HCV positive when screening was introduced. We have reviewed the Look Back cohort to identify those who did not develop any evidence of HCV infection despite confirmed high-dose exposure to HCV-contaminated blood products. We compared findings in these exposed uninfected cases with others who developed chronic infection or spontaneously resolved infection.

EU cohort

From a total of 1340 blood recipients identified in the Look Back programme, eight EU cases were stringently selected. The following criteria were used:

1) Definitive history of exposure to HCV from blood products;
2) Both HCV Ab and HCV ribonucleic acid (RNA) undetectable;
3) All EU cases received blood from HCV-infected donors whose blood donations had transmitted HCV to at least one recipient before and one recipient after donating blood to that EU individual, providing confirmation that the donor was infectious at the time of donation; or, the EU individual had to have received part of a blood donation that was responsible for infecting another recipient, thus confirming the donation itself was contaminated.
SR cohort

The SR cohort consisted of 10 blood recipients recruited from the Look Back programme who spontaneously cleared HCV following infection via blood transfusion, defined as anti-HCV Ab positive and HCV RNA negative.

Chronic infection cohort

A cohort of 10 treatment naïve patients with blood transfusion-acquired genotype 1 chronic HCV infection (anti-HCV Ab and HCV RNA positive for at least six months) were recruited from the South West Liver Unit clinic at Derriford Hospital, Plymouth.

Healthy control cohort

A cohort of 10 healthy controls with no risk factors for HCV was also recruited from Derriford Hospital and University of Plymouth.

Timing of HCV testing

All EU and SR blood recipients recruited from the Look Back programme were tested for HCV at the time of the programme (1995-1997) for anti-HCV Ab by a third-generation enzyme immunoassay (EIA) and HCV RNA by polymerase chain reaction (PCR). Median time from transfusion to the initial anti-HCV Ab testing was 7.4 years (interquartile range [IQR] 6.1-9.3) in EUs and 7.1 years (IQR 4.9-10.7) in SRs.

At study entry, each blood recipient was re-tested for anti-HCV Ab using a fourth-generation EIA assay, Monolisa HCV Ag-Ab Ultra (Bio-Rad Laboratories, Hertfordshire, UK), and for HCV RNA by PCR using the Cobas Ampliprep/Cobas Taqman HCV Test v2.0 (Roche, California, United States; lower limit of detection 15 IU mL-1).
Ethics

Ethics approval was granted by the UK Research Ethics Committee. All procedures were performed in accordance with the ethical standards of the Helsinki Declaration (1964, amended 2008) created by the World Medical Association. All participants provided informed written consent.

Peripheral blood mononuclear cells (PBMCs) isolation

PBMCs were isolated from whole blood using Ficoll (Sigma-Aldrich, Dorset, UK) density gradient centrifugation and cryopreserved for subsequent analyses [4,5].

Flow cytometry

Flow cytometry was performed using a four-channel BD Accuri C6 instrument (New Jersey, USA). Thawed PBMCs (1x10^6) were stained with the appropriate fluorescent-labelled monoclonal Ab/isotype, washed, and analysed. Ab labelled with FITC/PE/PerCP-Cy5.5/APC specific for the following human cell surface antigens were used: CD3, CD56, and CD16 from BD Biosciences (Oxford, UK); and KIR2DL1, CD158b, KIR2DL3, KIR2DL4, KIR2DS4, KIR3DL1, KIR3DL2, NKp30, NKp44, NKp46, NKG2A, NKG2C, and NKG2D from R&D Systems (Oxford, UK).

Cytotoxicity assay

Natural and interleukin (IL) 2-induced cytotoxicity of NK cells were measured against the target cell K562. NK cells were isolated from PBMCs using negative selection with the NK Cell Isolation Kit (Miltenyi Biotec, Surrey, UK). Isolated NK cells were cultured with/without IL2 (25 ng mL-1; R&D Systems) for 48 hours. Following culture, K562 cells, labelled with carboxyfluorescein succinimidyl ester (Fisher-Scientific, Leicester, UK), were
added to NK cells at an effector-to-target cell ratio of 0:1 (negative control) or 10:1 and incubated for four hours. Finally, 7-aminoactinomycin D (BD Biosciences) was added prior to flow cytometry.

**IFN-γ production**

Thawed PBMCs were stimulated with phorbol 12-myristate 13-acetate (Sigma-Aldrich) and ionomycin (Sigma-Aldrich) in the presence of brefeldin A (BD Golgi Plug, BD Biosciences) prior to incubation for four hours. After stimulation, cells were stained for CD3 and CD56 and then fixed and permeabilised using the BD Cytofix/Cytoperm Plus Fixation/Permeabilisation Kit (BD Biosciences). Following this, the cells were stained with fluorescent-labelled Ab for intracellular IFN-γ (BD Biosciences), washed, and analysed on the flow cytometer. Unstimulated PBMCs served as the negative control.

**IFN-γ enzyme-linked immunospot (ELISpot) assay**

ELISpot assays were performed as previously described [4,5]. Briefly, 200,000 PBMCs per well were cultured in triplicate with HCV peptides. The peptides spanned the entire genome of HCV genotypes 1b and 3a (BEI Resources, Virginia, United States) and were grouped into eight pools per genotype (core, E1, E2, p7 and NS2, NS3, NS4, NS5a, NS5b). Positive controls were: leucoagglutinin (PHA-L; Sigma-Aldrich); cytomegalovirus, Epstein-Barr virus, and influenza virus peptide pool (ProImmune, Oxford, UK); and cytomegalovirus pp65 peptide pool (ProImmune). Cells cultured in media alone acted as the negative control. After 16 hours of culture, the PBMCs were plated onto an ELISpot plate (Merck Millipore, Hertfordshire, UK) coated with IFN-γ Ab (BD Biosciences).
The mean number of spots was calculated for each triplicate. The number of spots in the negative control wells was subtracted from that of the antigen-treated wells and results expressed as spot-forming units per million cells (SFU per $10^6$ PBMCs). Assays with high background (negative control greater than five spots per well) or absent PHA-L responses were excluded. A response was defined as positive if the mean response in the antigen-treated well was more than twice the background value in the negative well and greater than three standard deviations above the mean response in the corresponding well of the healthy controls.

**Statistical analysis**

Statistical analysis was performed using IBM SPSS Statistics v20. Results were expressed as medians unless stated otherwise. Categorical data were compared using Fisher’s exact test. Continuous data between two cohorts were compared using Mann-Whitney-U test. With more than two cohorts, continuous data were compared using Kruskal-Wallis test. A statistically significant Kruskal-Wallis test was followed by post-hoc analysis using Dunn’s test for multiple comparisons between cohorts. Adjusted $p$ values were calculated to correct for multiple comparisons. Pearson product-moment correlation coefficient ($r$) was calculated for correlation analysis. A line of best fit was drawn using linear regression. Statistical significance levels were determined by two-tailed tests ($p<0.05$).
Results

Of the 1340 blood recipients identified as having received a contaminated blood product, 13 (0.97%) met the inclusion criteria for EU. Eleven were alive, of which eight were recruited into the study.

Baseline demographics and transfusion details of the eight EUs are shown in Table 1. Median age at time of transfusion was 21 years (IQR 13-32). There was no history of post-transfusion hepatitis. One participant, EU5, had biopsy-proven non-alcoholic fatty liver disease; the remaining seven had no history of liver disease or abnormal liver enzymes. There was a range of active medical conditions. No participant was on steroids or immunosuppression at the time of transfusion or recruitment.

Table 2 shows the donor-recipient records for each of the donors that donated blood to our EUs. In five cases, the donors (X1, X2, X3, X5, X7) infected other recipients both before and after donating blood to our EUs (EU1, EU2, EU3, EU5, EU7, respectively), confirming the donors were infectious during this time. In the remaining three cases, donors X4, X6, and X8 each made a donation that was separated into components and transfused to more than one recipient (X4 to EU4 and R9; X6 to EU6 and R13; X8 to EU8 and R19). The other recipients developed infection, thereby confirming the donation itself, which the three EUs had also received, was contaminated. In all cases, the genotypes of the infected recipients matched those of their respective donors.

A further 10 participants were recruited into each of the remaining three cohorts. There were no significant differences in the baseline characteristics between the four cohorts. Median ages at study entry were: 45 years (IQR 36-59) for the EU cohort, 67 years (IQR 47-71) for
the SR cohort, 52 years (IQR 43-61) for the cohort with chronic infection, and 46 years (IQR 39-53) for the healthy controls. In the EU, chronic infection, and healthy control cohorts, 50% were male; in the SR cohort, 40% were male.

EU blood recipients possessed higher numbers of NKp30+ NK cells

Fourteen activating and inhibitory NK cell receptors were studied on flow cytometry. NK cells were visualised as CD3-CD56+. The two functional subsets of NK cells, CD56\textsuperscript{bright} and CD56\textsuperscript{dim}, were defined by the varying intensities of CD56 expression. EUs were observed to have a higher proportion of NK cells than healthy controls and those with chronic infection (Figure 1); however, there was no difference in the distribution of NK cell subsets between EUs and the other cohorts, suggesting that the higher relative frequencies of NK cells in EUs were due to an increase in both CD56\textsuperscript{bright} and CD56\textsuperscript{dim} cells.

The numbers of NKp30+ NK cells were significantly higher in EUs than in the other cohorts – vs. SRs ($p=0.002$), vs. healthy controls ($p=0.01$), and vs. patients with chronic infection ($p=0.04$) (Figure 2A). This increased expression of NKp30 in EUs was observed across both subsets. EUs had significantly greater numbers of CD56\textsuperscript{dim} NKp30+ cells when compared to SRs ($p=0.007$) and healthy controls ($p=0.03$), and trending towards significance when compared with the chronic infection cohort ($p=0.06$) (Figure 2B). In the CD56\textsuperscript{bright} subset, numbers of NKp30+ cells were highest in the EUs, significant against SRs ($p=0.047$), healthy controls ($p=0.001$), and those with chronic infection ($p=0.02$) (Figure 2C).

Other differences in receptor expression were also observed. There were significantly higher levels of NKp80+ NK cells in EUs and SRs than in healthy controls, although not so when compared with the chronic infection cohort (Figure 3A). The expression of the inhibitory NK
cell receptors was also examined. The only significant difference was observed with the killer cell immunoglobulin-like receptor, KIR2DL3, which was preferentially expressed on CD56^{bright} NK cells of both EUs and SRs (Figure 3B).

**NKp30^{high} NK cells demonstrated enhanced IL2-induced cytotoxicity**

Cytotoxic activity of isolated NK cells (>90% purity) was determined to confirm whether differences in receptor expression were associated with enhanced killing potential. NK cells at rest had little cytotoxic activity and no differences were detected between cohorts. Following IL2 activation, NK cells of EUs had greater cytotoxicity than the other cohorts – vs. SRs ($p=0.06$), vs. healthy controls ($p=0.01$), and vs. those with chronic infection ($p=0.04$) (Figure 4A). As NKp30 was the only receptor that was preferentially upregulated in EUs, we looked for a potential relationship between NKp30 expression and NK cell cytotoxicity. IL2-induced NK cell cytotoxicity was positively correlated with NKp30 expression, although this correlation was weak ($r=0.38; p=0.02$) (Figure 4B).

NK cells can kill virus-infected cells indirectly by rapidly producing IFN-γ. At rest, very few NK cells produced IFN-γ with no differences observed between cohorts. Following stimulation, NK cell production of IFN-γ was increased in all subjects, although to a lesser extent in those with chronic infection. IFN-γ production by CD56^{dim} and CD56^{bright} NK cells in EUs was no different from SRs and healthy controls.

**T cell-mediated IFN-γ responses to HCV**

T cell responses to genotypes 1b and 3a were assessed in the eight EUs and compared with eight healthy controls. Positive IFN-γ responses were observed only in the EU group, with 4/8 demonstrating a positive response to at least one HCV-related peptide compared with
none in the healthy control group. Although the positive responses in the four EUs were weak, they were all multi-specific i.e. directed against multiple HCV proteins, which support true exposure rather than cross-reactivity with a non-HCV epitope. HCV proteins that were targeted were genotype 1b core, NS3, NS4, and NS5B proteins, and genotype 3a core, NS3, and NS5A proteins. The median times from HCV exposure to ELISpot testing in EUs were not significantly different between those with positive responses (23.6 years) and those without (25.3 years).
Discussion

This study describes a novel cohort of blood recipients with no clinical or serological evidence of infection despite verified exposure to HCV-contaminated blood. This is the first report of exposure without infection in the setting of large-volume intravenous inoculation of HCV with 8 cases identified and traced after meticulous interrogation of the records from a well conducted national look back exercise dating back to the 1990’s. Prior to this, exposure to HCV that did not result in infection had only been reported following much smaller inocula through IDU [4-16], sexual contact [21-23], or needle stick injury [24]. Transfusion-related HCV is, by and large, historical and so this cohort has considerable potential to advance our understanding of how high level resistance to HCV infection can be conferred.

We have shown that EU blood recipients have distinct differences in their NK cell phenotype and function. EUs had greater proportions of NK cells in the periphery, with a relative increase in both CD56\textsuperscript{bright} and CD56\textsuperscript{dim} subsets. One of the main findings was an activated receptor phenotype in EUs, with greater numbers of NKp30\textsuperscript{+} cells in both the CD56\textsuperscript{bright} and CD56\textsuperscript{dim} subsets, significantly higher than in the other groups. Thus, EU blood recipients not only possessed higher frequencies of NK cells, but their NK cells were richer in NKp30 compared to blood recipients with resolved or chronic infection. On functional analysis, activated NK cells in EUs displayed greater killing potential, with increased cytotoxicity but similar IFN-\(\gamma\) production. This enhanced killing potential of NK cells in EUs positively correlated with the expression of NKp30. These findings mirror those of two prospective studies conducted on IDUs; Sugden et al. [7] and Golden-Mason et al. [8] reported that increased NK cell cytotoxicity protected IDUs exposed to HCV from becoming infected and this enhanced cytotoxicity was associated with higher expression of NKp30. This study, therefore, supports NKp30-mediated NK cell cytotoxicity as a potential mechanism by which
individuals exposed to HCV are protected from infection, and appears to be relevant in both low- and high-dose exposures.

Other less striking differences were observed. NKp80 has an activating function, possibly by acting as co-receptor with other activating receptors [25]. EUs and SRs had significantly higher frequencies of NKp80+ NK cells than healthy controls, although levels were not statistically different when compared with those chronically infected. The significance of increased NKp80 levels is unclear; NKp80 has not previously been implicated in the immune defence against HCV. The levels of NKp80 did not correlate with cytotoxic activity, which could support the hypothesis that NKp80 alone has a limited role in NK cell activation, but acts instead as a co-receptor to potentiate the effect of a key receptor, such as NKp30.

KIR2DL3 has been associated with a favourable outcome following infection. HCV-infected IDUs have a higher chance of spontaneous clearance if they are homozygous for KIR2DL3 and HLA-C1. KIR2DL3 is a weaker inhibitor of NK cell activation than other inhibitory KIRs; thus, NK cells carrying this receptor are more easily activated [26]. The beneficial effect of KIR2DL3 and HLA-C1 extends beyond resolving infection, with our group and others showing that it may also play a part in preventing infection in IDUs exposed to HCV [9,13,15]. We now find KIR2DL3 to be associated with a favourable outcome in the setting of transfusion-related HCV exposure. Increased expression of KIR2DL3 was detected in both EUs and SRs, but only in the CD56^{bright} subset. KIRs are usually expressed at minimal levels on CD56^{bright} NK cells. Hence, upregulation of KIR2DL3 might render CD56^{bright} cells more easily activated and enhance their functional activity against HCV.
In this study, half of EU blood recipients demonstrated IFN-γ-producing T cell responses to HCV, similar to rates reported in both our [5] and other [7,10-12,24] IDU EU cohorts, where up to 60% have demonstrable T cell responses. Whilst these responses are often to multiple viral antigens, they are typically much weaker than those seen in SRs and the degree to which T cell responses confer protection from HCV infection is controversial. A nested case control series from a prospectively studied cohort of IDUs in Australia revealed no differences in T cell responses between those who developed incident HCV infection and those who remained uninfected, suggesting that whilst HCV-specific cellular immunity is prevalent in EUs, it does not correlate with protection [7]. Thus, whilst the presence of low-level HCV-specific T cell responses in half of our EU blood recipients provides further confirmation of HCV exposure, any role they have in protection remains unclear. The absence of response in the remaining EU blood recipients is consistent with previous studies that showed T cell responses waning over time [4,6], with HCV exposure in these recipients dating back over 20 years.

There are some limitations to this study. We defined EUs as being HCV antibody and HCV RNA negative. However, as the first testing for HCV antibodies took place some years after exposure, it is possible that they were infected but lost HCV antibodies over time. This has been reported in SRs, but typically 18-20 years after a low dose inoculation from anti-D immunoglobulin [27], whereas EUs identified in this cohort were all tested within 10 years from exposure. The sample size was limited by the small number of uninfected individuals that met the very strict definition of HCV exposure. EU blood recipients represent an extremely rare cohort and therefore, any study examining this unique group will be limited by small numbers and the difficulties that this poses. Furthermore, our results, like other studies on EU cohorts [4-16], were based on experiments using peripheral blood samples to obtain
NK and T cells, when we know that the immune response to the virus is reliant on intrahepatic immune cells. However, to study intrahepatic immune cells would require invasive sampling of the liver, which is difficult to justify in EUs who are otherwise healthy.

In summary, we have defined a novel cohort with a uniquely high level of resistance to HCV infection. This small group of cases, identified and traced from a painstaking review of a much larger cohort of HCV-exposed blood recipients, remained uninfected despite a clear history of high-dose parenteral exposure to HCV-contaminated blood. These EU blood recipients, similar to IDU EU cases, demonstrate distinct differences in their innate immunity, with an activated NK cell phenotype and enhanced cytotoxicity, together with low level adaptive HCV-specific T cell responses in half of these cases identified many years after the HCV exposure. It remains unclear if these differences alone are sufficient to explain the high level resistance demonstrated by these unusual cases and further study of this important group of cases to identify other potential mechanisms of protection from HCV infection are ongoing.
Acknowledgements and disclosures

Acknowledgements:

We would like to acknowledge NHS Blood and Transplant for granting us access to the Look Back Programme database and to all participants involved in the study.

Statement of interests

Authors declaration of personal interests:

None reported for all authors.

Declaration of funding interests:

This study was funded in full by the South West Liver Unit, Derriford Hospital, Plymouth, UK.
References


<table>
<thead>
<tr>
<th>ID</th>
<th>Age at entry (yrs)</th>
<th>Sex</th>
<th>Ethnicity</th>
<th>Date</th>
<th>Type of product</th>
<th>Indication</th>
<th>Other Symptoms of hepatitis risks</th>
<th>Abnormal liver enzymes</th>
<th>Active medical conditions</th>
<th>Immuno suppress ion</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU1</td>
<td>52</td>
<td>M</td>
<td>White British</td>
<td>05/08/1982</td>
<td>RBC</td>
<td>Trauma</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Hypertension</td>
</tr>
<tr>
<td>EU2</td>
<td>41</td>
<td>F</td>
<td>White British</td>
<td>07/01/1985</td>
<td>Platelet</td>
<td>Childhood ITP</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>EU3</td>
<td>32</td>
<td>M</td>
<td>White British</td>
<td>07/04/1987</td>
<td>Whole blood</td>
<td>Facial surgery</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Gout</td>
</tr>
<tr>
<td>EU4</td>
<td>72</td>
<td>F</td>
<td>White British</td>
<td>01/02/1989</td>
<td>RBC</td>
<td>Hysterectomy</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Hypertension, type II diabetes, No</td>
</tr>
<tr>
<td>EU5</td>
<td>61</td>
<td>F</td>
<td>White British</td>
<td>20/02/1989</td>
<td>Whole blood</td>
<td>Menorrhagia</td>
<td>No</td>
<td>No</td>
<td>NAFLD</td>
<td>Hypothyroidism on replacement No</td>
</tr>
<tr>
<td>EU6</td>
<td>48</td>
<td>M</td>
<td>Caribbean British</td>
<td>21/06/1990</td>
<td>RBC</td>
<td>Renal failure</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Haemodialysis</td>
</tr>
<tr>
<td>EU7</td>
<td>42</td>
<td>F</td>
<td>Caribbean British</td>
<td>29/10/1990</td>
<td>RBC</td>
<td>Sickle cell anaemia</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Sickle cell anaemia</td>
</tr>
<tr>
<td>EU8</td>
<td>34</td>
<td>M</td>
<td>White British</td>
<td>25/11/1990</td>
<td>RBC</td>
<td>Bone surgery</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Asthma</td>
</tr>
<tr>
<td>-----</td>
<td>----</td>
<td>---</td>
<td>---------------</td>
<td>------------</td>
<td>-----</td>
<td>--------------</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>--------</td>
</tr>
</tbody>
</table>

EU, exposed uninfected; yrs, years; M, male; F, female; HCV, hepatitis C; RBCs, red blood cells; ITP, idiopathic thrombocytopenic purpura; NAFLD, non-alcoholic fatty liver disease.
Table 2. Donations made by the donors of the eight EU participants and their corresponding recipients

<table>
<thead>
<tr>
<th>Donor</th>
<th>Donation</th>
<th>Recipient</th>
<th>Transfusion date</th>
<th>HCV test result by Lookback Programme</th>
</tr>
</thead>
<tbody>
<tr>
<td>X1</td>
<td>1</td>
<td>R1</td>
<td>17/03/1981</td>
<td>Infected – chronic HCV</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>EU1</td>
<td>05/08/1982</td>
<td>Uninfected</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>R2</td>
<td>05/01/1983</td>
<td>Infected – chronic HCV</td>
</tr>
<tr>
<td>X2</td>
<td>1</td>
<td>R3</td>
<td>03/03/1984</td>
<td>Infected – chronic HCV</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>EU2</td>
<td>07/01/1985</td>
<td>Uninfected</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>R4</td>
<td>29/04/1986</td>
<td>Infected – chronic HCV</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>R5</td>
<td>15/02/1987</td>
<td>Infected – spontaneous clearance</td>
</tr>
<tr>
<td>X3</td>
<td>1</td>
<td>R6</td>
<td>16/09/1983</td>
<td>Infected – spontaneous clearance</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>R7</td>
<td>22/09/1986</td>
<td>Infected – chronic HCV</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>EU3</td>
<td>07/04/1987</td>
<td>Uninfected</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>R8</td>
<td>16/10/1987</td>
<td>Infected – spontaneous clearance</td>
</tr>
<tr>
<td>X4</td>
<td>1</td>
<td>R9*</td>
<td>17/01/1989</td>
<td>Infected – chronic HCV</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>EU4*</td>
<td>01/02/1989</td>
<td>Uninfected</td>
</tr>
<tr>
<td>X5</td>
<td>1</td>
<td>R10</td>
<td>03/12/1987</td>
<td>Infected – spontaneous clearance</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>R11</td>
<td>08/09/1988</td>
<td>Infected – chronic HCV</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>EU5</td>
<td>20/02/1989</td>
<td>Uninfected</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>R12</td>
<td>26/01/1990</td>
<td>Infected – chronic HCV</td>
</tr>
<tr>
<td>X6</td>
<td>1</td>
<td>EU6*</td>
<td>21/06/1990</td>
<td>Uninfected</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>R13*</td>
<td>24/06/1990</td>
<td>Infected – chronic HCV</td>
</tr>
<tr>
<td>X7</td>
<td>1</td>
<td>R14</td>
<td>12/12/1985</td>
<td>Infected – chronic HCV</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>R15</td>
<td>03/08/1988</td>
<td>Infected – chronic HCV</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>R16</td>
<td>17/01/1990</td>
<td>Infected – chronic HCV</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>EU7</td>
<td>29/10/1990</td>
<td>Uninfected</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>R17</td>
<td>28/03/1991</td>
<td>Infected – chronic HCV</td>
</tr>
<tr>
<td>X8</td>
<td>1</td>
<td>R18</td>
<td>11/04/1989</td>
<td>Infected – spontaneous clearance</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>R19*</td>
<td>22/11/1990</td>
<td>Infected – spontaneous clearance</td>
</tr>
<tr>
<td></td>
<td>EU8*</td>
<td>25/11/1990</td>
<td>Uninfected</td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>------</td>
<td>------------</td>
<td>------------</td>
<td></td>
</tr>
</tbody>
</table>

*Received blood product from the same donation

EU, exposed uninfected; HCV, hepatitis C
Figure 1
Figure 2

A) NKp30 on NK cells

B) NKp30 on CD56\textsuperscript{dim} subset

C) NKp30 on CD56\textsuperscript{bright} subset

Figure 2
A) NKp80 on NK cells

B) KIR2DL3 on CD56^{bright} subset

Figure 3
**Figure 4**

(A) **IL2-induced cytotoxicity**

(B) **NKp30 on NK cells vs. IL2-induced cytotoxicity**

- IL2-induced cytotoxicity plot with different conditions (CON, EU, SR, CHR) showing % K562 Cell lysis and significance levels (p = 0.01 and p = 0.04).

- NKp30 on NK cells vs. IL2-induced cytotoxicity plot showing NKP30 expression (% of NK cells) and % K562 Cell lysis with a trend line and significance level (p = 0.02).